SG11201704792UA - Anti-csf1r antibodies for treating pvns - Google Patents

Anti-csf1r antibodies for treating pvns

Info

Publication number
SG11201704792UA
SG11201704792UA SG11201704792UA SG11201704792UA SG11201704792UA SG 11201704792U A SG11201704792U A SG 11201704792UA SG 11201704792U A SG11201704792U A SG 11201704792UA SG 11201704792U A SG11201704792U A SG 11201704792UA SG 11201704792U A SG11201704792U A SG 11201704792UA
Authority
SG
Singapore
Prior art keywords
csf1r antibodies
pvns
treating
treating pvns
csf1r
Prior art date
Application number
SG11201704792UA
Inventor
Robert Sikorski
Julie Hambleton
Nilacantan Sankar
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of SG11201704792UA publication Critical patent/SG11201704792UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201704792UA 2014-12-22 2015-12-21 Anti-csf1r antibodies for treating pvns SG11201704792UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095297P 2014-12-22 2014-12-22
US201562163251P 2015-05-18 2015-05-18
PCT/US2015/067012 WO2016106180A1 (en) 2014-12-22 2015-12-21 Anti-csf1r antibodies for treating pvns

Publications (1)

Publication Number Publication Date
SG11201704792UA true SG11201704792UA (en) 2017-07-28

Family

ID=55135539

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704792UA SG11201704792UA (en) 2014-12-22 2015-12-21 Anti-csf1r antibodies for treating pvns

Country Status (16)

Country Link
US (3) US10040858B2 (en)
EP (1) EP3237447B1 (en)
JP (1) JP6797801B2 (en)
KR (1) KR20170096187A (en)
CN (1) CN107257806B (en)
AU (1) AU2015369854B2 (en)
BR (1) BR112017013111A2 (en)
CA (1) CA2969341C (en)
EA (1) EA201791421A1 (en)
ES (1) ES2843586T3 (en)
HK (1) HK1245804A1 (en)
IL (1) IL252716A0 (en)
MX (1) MX2017008218A (en)
SG (1) SG11201704792UA (en)
TW (1) TW201630937A (en)
WO (1) WO2016106180A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
CN110709422B (en) 2017-04-19 2023-12-26 马伦戈治疗公司 Multispecific molecules and their uses
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11692029B2 (en) 2018-03-05 2023-07-04 The Schepens Eye Research Institute, Inc. Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
CN109053887B (en) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 A kind of anti-human CSF-1R monoclonal antibody and purposes
CN108948199B (en) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 Anti-human CSF-1R monoclonal antibody and application thereof
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
CN119857138A (en) * 2018-09-13 2025-04-22 豪夫迈·罗氏有限公司 CSF-1R antibody formulations
CN113164777B (en) 2018-09-27 2024-12-13 马伦戈治疗公司 CSF1R/CCR2 multispecific antibody
AU2020283742A1 (en) * 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
EP4051321A4 (en) 2019-10-30 2023-11-22 Duke University IMMUNOTHERAPY WITH COMBINATION THERAPY WITH AN IMMUNE TOXIN
WO2022132636A1 (en) * 2020-12-14 2022-06-23 AmMax Bio, Inc. High concentration formulations of anti-csf1 and anti-csf1r antibodies
US20260085124A1 (en) * 2022-09-12 2026-03-26 AmMax Bio, Inc. Treatment of tenosynovial giant cell tumor
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118593504B (en) * 2024-06-03 2025-03-18 北京大学第三医院（北京大学第三临床医学院） New use of deuterated colestitinib or its salt in preparing PVNS drugs
WO2025257419A1 (en) * 2024-06-13 2025-12-18 4Moving Biotech Glp-1 receptor agonist compounds for treating a proliferative synovial disorder

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0382781B1 (en) 1987-10-23 1993-09-29 Genetics Institute, Inc. Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0668914B1 (en) 1992-06-09 2000-08-16 Chiron Corporation Crystallization of m-csf
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
WO2001030381A2 (en) 1999-10-28 2001-05-03 Hofbauer, Reinhold Use of csf-1 inhibitors
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
DE60332483D1 (en) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic METHODS FOR THE PREVENTION AND TREATMENT OF CANCER METASTASIS AND CANCER LOSS ASSOCIATED WITH CANCER METASTASIS
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
JP2007524671A (en) 2004-01-21 2007-08-30 カイロン コーポレイション M-CSF muteins and uses thereof
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP2479277B1 (en) 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
CA2589895A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1945662A2 (en) 2005-11-10 2008-07-23 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
CN101379400A (en) 2005-12-22 2009-03-04 诺华有限公司 Soluble human M-CSF receptor and uses thereof
CN101534858A (en) 2006-01-05 2009-09-16 诺华有限公司 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2649288C (en) 2006-04-19 2015-11-24 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
JP2010510219A (en) 2006-11-17 2010-04-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド Systemic administration of colony stimulating factor to treat amyloid-related disorders
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
PL2188313T3 (en) 2007-08-21 2018-04-30 Amgen, Inc. Human c-fms antigen binding proteins
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
BRPI0818003A2 (en) 2007-10-18 2019-09-24 Novartis Ag csf-1r inhibitors, compositions and methods of use
WO2009058968A2 (en) 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
BRPI0909044B8 (en) 2008-03-14 2021-05-25 Transgene Sa antibody that specifically binds to human csf-1r, pharmaceutical composition and use thereof
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP5767965B2 (en) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． 5H-pyrrolo [2,3-B] pyrazine derivatives that regulate kinases and indications thereof
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
CN106220623A (en) 2009-11-06 2016-12-14 普莱希科公司 Compounds and methods for and indication thereof for kinases regulation
ES2722300T3 (en) 2009-12-10 2019-08-09 Hoffmann La Roche Antibodies that preferentially bind to extracellular domain 4 of CSF1R and its use
PL2516433T3 (en) 2009-12-21 2014-10-31 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (en) * 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Antibody to human CSF-1R and use thereof
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
HRP20190047T1 (en) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Antibodies Bind to CSF1R
TW201307845A (en) 2010-12-13 2013-02-16 Novartis Ag Predictive methods and methods of treating arthritis using IL-17 antagonists
US20140288279A1 (en) 2011-10-21 2014-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
US10660882B2 (en) * 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
RU2670743C9 (en) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107759690A (en) 2012-08-31 2018-03-06 戊瑞治疗有限公司 With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R)

Also Published As

Publication number Publication date
US10730949B2 (en) 2020-08-04
HK1245804A1 (en) 2018-08-31
CA2969341C (en) 2023-07-04
WO2016106180A1 (en) 2016-06-30
MX2017008218A (en) 2017-10-18
CN107257806B (en) 2021-08-10
TW201630937A (en) 2016-09-01
KR20170096187A (en) 2017-08-23
EP3237447A1 (en) 2017-11-01
BR112017013111A2 (en) 2018-05-15
EP3237447B1 (en) 2020-12-02
CN107257806A (en) 2017-10-17
US10040858B2 (en) 2018-08-07
AU2015369854B2 (en) 2021-07-01
US20210009700A1 (en) 2021-01-14
EA201791421A1 (en) 2017-10-31
JP2018501254A (en) 2018-01-18
JP6797801B2 (en) 2020-12-09
IL252716A0 (en) 2017-08-31
US20190119390A1 (en) 2019-04-25
ES2843586T3 (en) 2021-07-19
AU2015369854A1 (en) 2017-06-15
US20160185869A1 (en) 2016-06-30
CA2969341A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
IL250583A0 (en) Anti-tigit antibodies
IL252004A0 (en) Domain-exchanged antibody
IL252716A0 (en) Anti-csf1r antibodies for treating pvns
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
PT3492632T (en) Methods for treating lithium-containing materials
IL254393A0 (en) Methods for treating proteinopathies
GB201410520D0 (en) Antibody
IL248220A0 (en) Anti-nme antibody
IL250374A0 (en) Anti-ceramide antibodies
IL249475A0 (en) Methods for treating pruritus
SG11201605070UA (en) Novel methods for treating cancer
IL247988A0 (en) Antibodies against hpa-1a
SG11201700922YA (en) Anti-orai1 antibody
GB201417447D0 (en) Improved immunoassay for pyrrolidinophenones
PL3113919T3 (en) Process for edgebanding
IL249616A0 (en) Methods for treating infections
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201418776D0 (en) Antibody